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A B S T R A C T   
Lack of coordination between the DNA replication and transcription machineries can increase the frequency of 
transcription–replication conflicts, leading ultimately to DNA damage and genomic instability. A major source of 
these conflicts is the formation of R-loops, which consist of a transcriptionally generated RNA–DNA hybrid and 
the displaced single-stranded DNA. R-loops play important physiological roles and have been implicated in 
human diseases. Although these structures have been extensively studied, many aspects of R-loop biology and R- 
loop–mediated genome instability remain unclear. We found that in cancer cells, tonicity-responsive enhancer- 
binding protein (TonEBP, also called NFAT5) interacted with PARP1 and localized to R-loops in response to DNA- 
damaging agent camptothecin (CPT), which is associated with R-loop formation. PARP1-mediated PARylation 
was required for recruitment of TonEBP to the sites of R-loop–associated DNA damage. Loss of TonEBP increased 
levels of R-loop accumulation and DNA damage, and promoted cell death in response to CPT. These findings 
suggest that TonEBP mediates resistance to CPT-induced cell death by preventing R-loop accumulation in cancer 
cells.   
1. Introduction 
Maintenance of genome integrity depends on spatiotemporal coor-
dination between the DNA replication and transcription machineries. 
Lack of such coordination can lead to DNA damage and genomic 
instability resulting from an elevated frequency of tran-
scription–replication conflicts [1,2]. A major source of these conflicts is 
the formation of R-loops, which consist of a co-transcriptionally gener-
ated RNA–DNA hybrid and the displaced single-stranded DNA [3]. 
R-loops, which arise naturally during transcription in organisms from 
bacteria to mammals, play multiple roles in cellular processes, including 
regulation of gene expression [4], transcription termination [5], and 
DNA replication [6]. In addition to these physiological functions, 
R-loops also threaten genome integrity, resulting in deleterious effects 
on the cell [7–9]. Abnormal accumulation of R-loops and collisions with 
replication forks can increase the rate of DNA damage and genome 
instability [2,10]. R-loops have been implicated in many human dis-
eases, including neurological disorders, cancer, and autoimmunity [11, 
12]. Accordingly, R-loops must be tightly regulated in living cells. 
R-loop homeostasis is regulated by the factors and cellular processes 
that control the formation and resolution of these structures. In humans, 
proteins involved in chromatin modification and the DNA damage 
response play important roles in maintaining the proper R-loop balance 
[13–15], and aberrant expression or function of these factors can 
contribute to disease [16,17]. Moreover, R-loops can regulate gene 
expression by recruiting protein factors [13]. However, the molecular 
mechanisms linking these factors to R-loop biology remain unclear, and 
we require a clearer understanding of their identities and the mecha-
nisms by which they are recruited. 
Tonicity-responsive enhancer-binding protein (TonEBP), also known 
as nuclear factor of activated T-cells 5 (NFAT5), is a pleiotropic stress 
protein involved in the response to various types of stress [18]. TonEBP 
can promote physiological or pathological consequences depending on 
the context: for example, TonEBP-mediated responses to osmotic stress 
[19–22] and bacterial infection [23] have protective functions, whereas 
the responses to autoimmune and metabolic stresses contribute to the 
pathogenesis of human diseases such as rheumatoid arthritis [24,25], 
atherosclerosis [26], hepatocellular carcinoma (HCC) [27,28], obesity 
[29], and diabetes mellitus [29,30]. Although TonEBP has 
well-established functions in the responses to a range of cellular stresses, 
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its role in the cellular response to DNA damage remains to be elucidated. 
To systematically explore the cellular functions of TonEBP, we analyzed 
proteins that interacted with TonEBP using tandem affinity 
purification-mass spectrometry. The results of that study revealed that 
TonEBP interacts with DNA repair proteins; in addition, TonEBP is 
recruited to DNA damage sites and protects cells from genotoxic stress 
[31]. TonEBP mediates DNA damage tolerance through ubiquitination 
of proliferating cell nuclear antigen (PCNA), a DNA clamp required for 
replication and repair. Furthermore, TonEBP is involved in the dynamic 
association of DNA repair proteins and their recruitment to DNA damage 
sites. Our interactomic data also revealed that TonEBP associates with 
proteins that resolve R-loop structures, such as RNA helicases and in-
hibitors of R-loop accumulation (31, Supplementary Fig. 1), raising the 
possibility that it plays a role in R-loop biology. 
In this study, we explored the role of TonEBP in R-loop–associated 
DNA damage. We found that in cancer cells, TonEBP interacted with 
poly (ADP-ribose) polymerase 1 (PARP1), localized to R-loops, and 
prevented R-loop accumulation and DNA damage in response to an R- 
loop–associated DNA-damaging agent. Together, these findings suggest 
that TonEBP mediates resistance to DNA damage by preventing R-loop 
accumulation in oncogenic cells. These findings provide new insights 
into the molecular mechanisms underlying DNA damage and repair 
responses, and reveal novel functions of TonEBP in R-loop biology. 
2. Results 
2.1. TonEBP interacts with, and is PARylated by, PARP1 
Our interactomic data from a previous study revealed that TonEBP 
interacts with proteins involved in R-loop resolution, including PARP1 
and RNA helicases (31, Supplementary Fig. 1). Given the pivotal role of 
PARP1 in resolving R-loop–associated DNA damage [13], we decided to 
investigate the interaction between TonEBP and PARP1, and its role in 
R-loop biology. To this end, we first sought to determine whether 
TonEBP physically binds to PARP1. Co-immunoprecipitation (co-IP) 
experiments in HEK293 T cells revealed that endogenous TonEBP and 
PARP1 proteins interact (Fig. 1A). Next, we defined the molecular basis 
of the TonEBP–PARP1 interaction using constructs expressing several 
recombinant variants of TonEBP (Fig. 1B) and PARP1 (Fig. 1C). Con-
structs containing the Rel-homology domain (RHD), including 
full-length TonEBP and Yc1 (N terminus of TonEBP), interacted with 
PARP1, whereas a mutant lacking the RHD (ΔRHD) did not (Fig. 1D), 
indicating that the RHD of TonEBP is essential for its interaction with 
PARP1. To determine which structural elements of PARP1 are required 
for the interaction with TonEBP, we transfected cells with constructs 
expressing Yc1 and full-length PARP1 or a deletion mutant. Full-length 
PARP1 and the catalytic domain (CatD) both bound to Yc1, whereas the 
DNA-binding domain and BRCA1 C-terminal domain did not (Fig. 1E). 
These data indicate that the RHD of TonEBP and the CatD of PARP1 
mediate the interaction between the two proteins. 
In response to DNA damage, PARP1 is activated and promotes the 
formation of poly (ADP-ribose) polymer on its substrates [32]. In light of 
Fig. 1. TonEBP interacts with PARP1 
through the Rel-homology domain. 
(A) HEK293 T cells were immunoprecipitated 
(IP) with normal serum (Serum) or anti-TonEBP 
antibody (TonEBP). Cell lysates (input) and 
precipitated proteins were immunoblotted for 
TonEBP and PARP1. (B) Domain structures of 
human TonEBP and deletion constructs Yc1 and 
ΔRHD. (C) Domain structures of human PARP1 
and deletion constructs containing the DNA- 
binding domain (DBD), BRCA1 C-terminal 
domain (BRCT), or catalytic domain (CatD). (D) 
U2OS cells were transfected with a plasmid 
expressing Myc-tagged TonEBP, Yc1, or ΔRHD 
for 24 h. Cell lysates were immunoprecipitated 
with anti-Myc antibody. Cell lysates and 
precipitated proteins were immunoblotted for 
PARP1 and Myc. (E) U2OS cells were trans-
fected for 24 h with plasmids expressing Myc- 
Yc1 in combination with FLAG tagged PARP1, 
DBD, BRCT, or CatD. Cell lysates were immu-
noprecipitated with anti-Myc antibody. Cell 
lysates and precipitated proteins were immu-
noblotted for FLAG and Myc.   
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the observation that TonEBP interacts with PARP1, we asked whether 
TonEBP was poly-ADP-ribosylated (PARylated) by PARP1 in 
Yc1-overexpressing cells. For these studies, we used the U2OS human 
osteosarcoma cell line, which has a robust and well-characterized 
response to DNA damage, and camptothecin (CPT), which promotes 
R-loop–associated DNA damage. The content of PARylated protein 
increased in a time-dependent manner in response to CPT (Fig. 2A, 
bottom panel). Notably, co-IP experiments revealed that CPT induced 
increased PARylation intensity and up-shifting smears of Yc1 (Fig. 2A, 
top panel), and this effect was abrogated by the PARP1 inhibitor ola-
parib (Fig. 2B). The interaction between TonEBP and PARP1 remained 
even after PARylation of TonEBP (Fig. 2A, top panel). Next, we exam-
ined whether PARylation of TonEBP in response to CPT was mediated by 
the binding. PARylation of TonEBP was dramatically reduced in the 
PARP1 knockout cells (Fig. 2C), whereas PARP1 overexpression induced 
a clear increase both in basal and CPT-induced PARylation of TonEBP 
(Fig. 2D). In addition, the ΔRHD mutant was not PARylated (Fig. 2E). 
Together, these data demonstrate that TonEBP interacts with PARP1, 
and that PARP1 mediates the PARylation of TonEBP in response to CPT. 
2.2. PARylation of TonEBP mediated by PARP1 triggers recruitment of 
TonEBP to sites of DNA damage 
PARylation of target proteins by PARP1 is one of the earliest steps in 
the cellular response to DNA lesions, leading to activation of DNA 
damage response pathways and facilitating DNA damage repair. Indeed, 
many DNA repair factors are PARylated to access DNA damage sites 
[32]. Our previous study provided evidence that TonEBP is recruited to 
DNA damage sites and promotes the DNA damage bypass pathway [31]. 
Hence, we investigated whether PARP1 is required for recruitment of 
TonEBP to DNA damage sites. To this end, we performed laser 
micro-irradiation to induce double-strand breaks in DNA and then 
examined laser damage-induced recruitment of GFP-tagged Yc1 pro-
teins. Yc1, which contains the RHD of TonEBP, was translocated to the 
micro-irradiated region of the nucleus, but this translocation was not 
observed in olaparib- or PARP1-siRNA–treated cells (Fig. 3A and B). 
Furthermore, we examined DNA damage-induced foci formation of 
TonEBP in response to CPT and found that both pretreatment with 
olaparib and knockdown of PARP1 significantly inhibited the 
CPT-mediated formation of TonEBP foci (Fig. 3C). 
CPT-induced DNA Topoisomerase 1 cleavage complex formation is 
the major source of DNA damage, most likely through replication- 
induced DNA damage [33,34] and R-loop is one of the sources of DNA 
Fig. 2. PARP1 mediates PARylation of 
TonEBP in response to camptothecin. 
(A) U2OS cells transfected with Yc1 were 
treated with 10 μM camptothecin (CPT) for the 
indicated times (0–2 h). Proteins were immu-
noprecipitated (IP) with anti-TonEBP antibody 
(TonEBP). Precipitates and cell lysates were 
immunoblotted for PAR (poly (ADP-ribose)), 
PARP1 and TonEBP. *, PARylated proteins. (B) 
The cells were pretreated with 1 μM olaparib 
for 1 h, followed by treatment with 10 μM CPT 
for 2 h as indicated. Cell lysates were prepared 
and immunoprecipitated with anti-TonEBP 
antibody. Precipitates and cell lysates were 
immunoblotted for PAR and TonEBP. (C) 
PARP1 wild type (WT) or knockout (KO) HEK- 
293 T cells transfected with Yc1 were treated 
with 10 μM CPT for 2 h. Cells were then 
immunoprecipitated with anti-TonEBP anti-
body. Precipitates and cell lysates were immu-
noblotted for PAR, PARP1 and TonEBP. (D) 
U2OS cells transfected with Yc1 were trans-
fected a second time with a plasmid expressing 
FLAG-empty (-) or FLAG-PARP1 (+) for 24 h. 
The transfected cells were treated with 10 μM 
CPT for 2 h and then immunoprecipitated with 
anti-TonEBP antibody. Precipitates and cell ly-
sates were immunoblotted for PAR, PARP1 and 
TonEBP. (E) U2OS cells were transfected with 
ΔRHD mutant of TonEBP and treated with 10 
μM CPT for 2 h. Cells were then immunopre-
cipitated with anti-TonEBP antibody. Pre-
cipitates and cell lysates were immunoblotted 
for PAR and TonEBP.   
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damage following CPT treatment [35–37]. Our recent data show that 
TonEBP is recruited to R-loops in response to CPT and mediates R-loop 
resolution via RNaseH1 recruitment [38]. Thus, we asked whether 
PARylation of TonEBP is required for R-loop recognition. To answer this 
question, we performed a proximity ligation assay (PLA) with anti-
–DNA/RNA hybrid (S9.6) and anti-TonEBP antibodies, enabling us to 
monitor the interaction between R-loop–enriched foci and TonEBP. We 
observed PLA signals in the nucleus following CPT treatment but to a 
lesser extent in cells treated with olaparib (Fig. 3D). These data indicate 
that PARP1-dependent PARylation of TonEBP was essential for its 
recruitment to sites of R-loop–associated DNA damage in response to 
CPT. Furthermore, olaparib significantly inhibited recruitment of RNase 
H1 to R-loops at both basal and CPT-treated conditions (Fig. 3E), 
demonstrating that PARylation was required for recruitment of RNase 
Fig. 3. PARylation of TonEBP mediated by 
PARP1 is required for recruitment of 
TonEBP to sites of R-loop-associated DNA 
damage. 
(A and B) U2OS cells transfected with scram-
bled (Scr) or PARP1-targeted siRNA (si-PARP1) 
were transfected again with GFP-Yc1 for 24 h. 
The cells were then subjected to laser micro- 
irradiation after pretreatment with vehicle (-) 
or 1 μM olaparib for 30 min. (A) After irradia-
tion, green fluorescence images were acquired 
at the indicated times (0–60 sec). (B) The 
fluorescence intensity in the micro-irradiated 
area at indicated time point was determined 
from 10 cells. Data (means ± SD) were obtained 
from three independent experiments (n = 3). * p 
< 0.01 compared to Scr; -. (C) Cells were 
transfected with siRNA and treated with ola-
parib, as in A and B. Cells were then treated 
with vehicle (-) or 10 μM CPT, followed by 
immunostaining for TonEBP. (Left) Represen-
tative images. (Right) Numbers of TonEBP foci 
(means ± SD) were determined from at least 50 
cells in each condition. * p < 0.01. (D and E) 
Cells were pretreated with vehicle (-) or 1 μM 
olaparib followed by treatment with vehicle (-) 
or 10 μM CPT. The cells were then subjected to 
PLA between TonEBP and R-loops (D), or 
RNaseH1 and R-loops (E). (Left) Representative 
images. (Right) Percentages of PLA signal- 
positive nuclei were calculated from at least 
30 cells. Data (means ± SD) are from three in-
dependent experiments (n = 3). * p < 0.01.   
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H1 to sites of R-loops. 
2.3. PARP1-mediated PARylation of TonEBP prevents R-loop 
accumulation 
Next, we investigated the potential role of TonEBP and its PAR-
ylation in the R-loop response following CPT treatment using cells in 
which TonEBP had been knocked down with siRNA. Immunocyto-
chemistry experiments with S9.6 antibodies revealed that the global 
level of R-loops was elevated in TonEBP-depleted cells irrespective of 
CPT treatment (Fig. 4A and B). The R-loop signal was also elevated upon 
PARP inhibition with olaparib, as previously reported [13]. However, 
PARP inhibition did not further increase the R-loop signal in 
TonEBP-depleted cells, again irrespective of CPT treatment (Fig. 4A and 
B), suggesting that TonEBP and PARP1 act in the same pathway to 
suppress R-loops. 
Excessive R-loop accumulation triggers DNA damage and genome 
instability [3,7]. Hence, we asked whether R-loop accumulation in 
TonEBP-depleted cells increases the rate of DNA damage. To answer this 
question, we analyzed γH2AX and 53BP1 foci, which are markers of 
DNA damage. Consistent with the accumulation of R-loops (Fig. 4A), 
TonEBP depleted cells had significantly increased levels of γH2AX and 
53BP1 foci, irrespective of CPT treatment (Fig. 4C-F). Pretreatment with 
olaparib also significantly increased the intensities of γH2AX and 53BP1 
(Fig. 4C–F). By contrast, in TonEBP-depleted cells, olaparib did not 
further increase formation of γH2AX and 53BP1 foci, irrespective of CPT 
treatment, suggesting that TonEBP and PARP1 are epistatic for signaling 
or repair of DNA damage induced by CPT. 
These data, together with our data in Figs. 3 and 4, indicate that 
PARP1-mediated PARylation of TonEBP is required to prevent R-loop 
accumulation and DNA damage. 
2.4. The RHD of TonEBP is required to prevent R-loop–associated DNA 
damage and cell survival in response to CPT 
To further explore our observation that RHD of TonEBP was required 
Fig. 4. PARP1-mediated PARylation of 
TonEBP prevents R-loop–associated DNA 
damage. 
U2OS cells were transfected with scrambled 
siRNA (-) or TonEBP-targeting siRNA (si-Ton) 
for 24 h. The cells were then untreated (-) or 
pretreated (+) with 1 μM olaparib for 1 h, fol-
lowed by treatment with either 10 μM CPT or 
vehicle alone (Veh) for 3 h. (A) R-loops and 
nuclei were visualized by immunostaining with 
S9.6 antibody and DAPI staining, respectively. 
(B) S9.6 foci per nucleus were counted from 30 
cells (means ± SD). (C–F) Immunostaining was 
performed for γH2AX and 53BP1. Representa-
tive images for γH2AX (C) and 53BP1 (E) were 
shown. Percentages of γH2AX (D) and 53BP1 
(F) foci-positive cells were calculated from at 
least 30 cells. Data (means ± SD) are from three 
independent experiments (n = 3). * p < 0.01, n. 
s.: not significant.   
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for PARylation via an interaction with PARP1 (Figs. 1 and 2), we per-
formed rescue experiments to determine whether the RHD of TonEBP is 
required for R-loop resolution, maintenance of genome integrity, and 
cell survival. We first examined whether RHD of TonEBP is critical for R- 
loop binding, which is required for function of TonEBP at R-loops, using 
PLA in cells overexpressing intact TonEBP or ΔRHD. The PLA signals 
were observed in cells overexpressing intact TonEBP but not in ΔRHD 
mutant (Fig. 5A), indicating that the RHD of TonEBP is critical for R-loop 
binding. More importantly, the re-expression of intact TonEBP (Fig. 5B) 
rescued the increase in R-loop accumulation caused by TonEBP deple-
tion, whereas re-expression of the ΔRHD mutant did not (Fig. 5C-D). 
Moreover, the ΔRHD mutant did not revert the increase in abundance of 
53BP1 foci in TonEBP-depleted cells (Fig. 5E and F). Consistent with the 
higher levels of R-loop accumulation and DNA damage, depletion of 
TonEBP enhanced the dose dependent cell death by treatment with CPT 
(Fig. 5G and H). Overexpression of intact TonEBP abolished this 
Fig. 5. RHD of TonEBP is required for pre-
vention of R-loop–associated DNA damage 
and cell survival in response to CPT. 
(A) U2OS cells were transfected with plasmid 
expressing full-length TonEBP (FL) or ΔRHD for 
24 h. The cells were then subjected to PLA be-
tween TonEBP and R-loops. Representative 
images are shown. (B-H) U2OS cells were 
transfected with scrambled siRNA (Scr or -) or 
TonEBP-targeting siRNA (si-Ton) for 24 h. The 
siRNA-transfected U2OS cells were then trans-
fected a second time with plasmid expressing 
full-length TonEBP (FL) or ΔRHD for 24 h. (B) 
Cell lysates were immunoblotted for TonEBP 
and HSC70. Representative images are shown. 
(C) R-loop and nuclei were visualized by im-
munostaining with S9.6 antibody and DAPI 
staining, respectively. (D) The number of S9.6 
foci per nucleus was determined from at least 
30 cells. (E) Immunostaining was performed for 
53BP1. Representative images are shown. (F) 
Percent of 53BP1 foci-positive cells was calcu-
lated from at least 30 cells. (G and H) The 
transfected cells were treated with vehicle (-) or 
2.5, 5, or 10 μM of CPT. Cell viability was 
assessed by MTT reduction (F) and LDH release 
(G) after 24 h. Data (means ± SD) were from 
three independent experiments (n = 3). * p <
0.05.   
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increase, whereas overexpression of the ΔRHD mutant did not (Fig. 5G 
and H). Taken together, these data suggest that the RHD of TonEBP 
prevents R-loop accumulation and DNA damage, and promotes cell 
survival, following CPT treatment. 
2.5. TonEBP prevents R-loop–mediated DNA damage in HepG2 human 
hepatoma cells 
The findings described above indicated that PARP1-mediated PAR-
ylation of TonEBP promotes DNA repair and cell survival in human 
osteosarcoma U2OS cells. Given that TonEBP [27,28] and PARP1 [39] 
are key drivers of HCC tumorigenesis, and that their inhibition sup-
presses HCC progression, we investigated the potential role of the 
PARP1–TonEBP axis in R-loop–associated DNA damage in HepG2 
human hepatoma cells. siRNA-mediated depletion of TonEBP in HepG2 
cells increased R-loop accumulation in both the presence and absence of 
CPT (Fig. 6A and B), and led to a defect in the incorporation of the 
thymidine analog 5-ethynyl-2′-deoxyuridine (EdU) (Fig. 6C and D), 
indicating that TonEBP depletion promotes R-loop accumulation and 
DNA replication defects. Interestingly, TonEBP depletion exerted syn-
ergistic effects on olaparib-induced cell death in CPT-untreated cells 
(Fig. 6E and F). TonEBP depletion and olaparib increased sensitivity to 
cell death in response to CPT treatment (Fig. 6E and F). However, ola-
parib treatment of TonEBP-depleted cells did not further increase cell 
death in response to CPT (Fig. 6E and F), as in the case of U2OS cells. 
Taken together, these data indicate that the PARP1–TonEBP axis sup-
presses R-loop–associated DNA damage and cell death in cancer cells. 
3. Discussion 
TonEBP is a well-established transcriptional regulator that serves as 
both an activator and a repressor [18]. TonEBP regulates transcription 
of a large number of genes, either by direct binding to DNA via a specific 
motif or indirect binding via an interacting protein. Beyond its role as a 
transcriptional regulator, TonEBP is recruited to sites of DNA damage 
and promotes error-prone DNA damage bypass (controlled by PCNA) in 
response to genotoxic stress [31]. Given that one of the hallmarks of 
cancer is widespread genomic instability, this implies that TonEBP is 
Fig. 6. TonEBP prevents R-loop–mediated 
DNA damage in HepG2 human hepatoma 
cells. 
(A and B) HepG2 cells were transfected with 
scrambled siRNA (Scr) or TonEBP-targeting 
siRNA (si-Ton) for 24 h. The cells were then 
treated with vehicle (-) or 10 μM CPT. R-loop 
and nuclei were visualized by immunostaining 
with S9.6 antibody and DAPI staining, respec-
tively (A). The number of S9.6 foci per nucleus 
was determined from at least 30 cells (B). (C 
and D) HepG2 cells were transfected with 
siRNA as above, and then subjected to Click-iT 
EdU assay. (C) Representative images of cells 
in each condition. (D) Percent of EdU positive 
cells were measured. Mean ± SD, n = 3. *p <
0.01. (E and F) HepG2 cells were transfected 
with siRNA and then treated with vehicle (-) or 
1 μM olaparib for 1 h in the absence (-) or 
presence 10 μM CPT as indicated. Cell viability 
was assessed by MTT assay (E) and LDH release 
(F) after 24 h. Data (means ± SD) are from 
three independent experiments (n = 3). * p <
0.01. n.s.: not significant. (G) Model: PARP1- 
mediated PARylation of TonEBP prevents R- 
loop–associated DNA damage.   
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involved in human cancer. Indeed, TonEBP facilitates DNA repair via 
recruitment of a prominent DNA repair protein, the ERCC1/XPF com-
plex, and consequently promotes self-renewal and chemoresistance of 
liver stem cells in response to cisplatin, a DNA-damaging agent that is 
widely used as an anticancer drug [28]. However, it remains to be 
determined how TonEBP is recruited to sites of DNA damage, and which 
factors influence its functions in DNA damage and repair response. 
Our primary finding of this study was that TonEBP interacts with 
PARP1, and that PARP1-mediated PARylation is necessary for recruit-
ment of TonEBP to sites of DNA damage. PARP1 associates with TonEBP 
in cells exposed to high NaCl and suppresses its transcriptional activity 
[40]. One intriguing possibility is that in addition to promoting 
recruitment of TonEBP to sites of DNA damage, PARylation of TonEBP is 
required for regulation of its transcriptional activity. Consistent with 
this idea, it is already known that transcriptional activity of TonEBP is 
regulated by post-translational modification, including phosphorylation 
[11] and sumoylation [41]. Future studies should investigate the impact 
of the TonEBP–PARP1 interaction on other cellular responses, including 
transcriptional regulation. 
PARP1 is an important DNA repair molecule [32], and the successful 
application of PARP1 inhibitors in treating cancer is a classic example of 
the rational development of DNA repair-targeted cancer therapy [42]. 
Specifically, olaparib suppresses HCC growth in mouse and HCC 
patient-derived xenograft models [39]. TonEBP also acts as an onco-
protein via multiple mechanisms in HCC [27,28]. TonEBP plays a crit-
ical role in tumorigenesis and tumor progression by activating the NF-κB 
enhanceosome and upregulating COX2 expression [27]. It also promotes 
stemness of liver cancer and cisplatin resistance via recruitment of the 
ERCC1/XPF dimer [28]. Interestingly, PARP and the ERCC1/XPF com-
plex participate in distinct DNA damage repair pathways [43]. This 
study demonstrated that PARP is involved in a common repair pathway 
with tyrosyl-DNA phosphodiesterase 1, and that the ERCC1/XPF com-
plex is involved in DNA repair by inducing the γH2AX response. Based 
on these findings, we speculate that TonEBP may be involved in 
tumorigenesis and tumor progression via both DNA repair pathways 
involving PARP and XPF-ERCC1 in liver cancer, although additional 
studies focusing on this issue are still required. 
R-loops play important physiological roles and have been implicated 
in pathogenesis [13–17]. Although the factors and cellular processes 
associated with R-loops have been extensively studied, many aspects of 
R-loop biology and R-loop–mediated genome instability remain unclear. 
Given the multifaceted roles of TonEBP and PARP1 in cancers, we 
focused on the PARP1-mediated function of TonEBP in R-loop-
–associated DNA damage in cancer cells, and identified TonEBP as a 
novel regulator of R-loop–associated DNA damage. We showed that 
TonEBP is recruited to R-loop–forming loci in response to the R-loop-
–associated DNA-damaging agent CPT. The loss of TonEBP increased the 
levels of R-loop accumulation, DNA damage, and DNA replication 
defect, thereby increasing the rate of CPT-mediated cell death, demon-
strating that TonEBP plays an important general role in resolving 
R-loop–associated DNA damage in cancer cells. This finding is supported 
by our recent study showing that the overexpression of 
catalytically-active RNaseH1, a conserved enzyme that performs R-loop 
resolution, recovered the increase of DNA damage and the reduction of 
cell proliferation induced by TonEBP depletion [38]. 
Similar results were obtained by knocking down or inhibiting of 
PARP1. However, loss of PARP1 function did not further increase R- 
loop–associated DNA damage in TonEBP-depleted cells, suggesting that 
TonEBP and PARP1 act in the same pathway to resolve replication stress, 
coordinate DNA repair, and promote cell survival (Fig. 6G). These 
findings provide new insights into the molecular mechanisms underly-
ing cellular DNA damage and repair response, as well as the novel 
functions of TonEBP in R-loop biology. 
In summary, we have shown that in cancer cells, TonEBP is PARy-
lated via an interaction with PARP1, localizes to R-loops, prevents R- 
loop accumulation and DNA damage, and protects against cell death 
induced by an R-loop–associated DNA-damaging agent. These findings 
suggest that TonEBP mediates resistance to CPT-induced cell death by 
preventing R-loop accumulation in cancer cells. Therefore, TonEBP or its 
protein–protein interactions represent potential therapeutic targets for 
human disorders associated with dysregulation of R-loop structures. One 
important issue to be addressed is how the same DNA damage response 
(DDR) stimulus can lead to markedly different responses, and how 
complex pathways and events are orchestrated. A better understanding 
of DDR will open new avenues for rational disease management. 
4. Materials and methods 
4.1. Cells and reagents 
HEK293T (ATCC CRL-3216), U2OS (ATCC HTB-96) cells were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with 10 % fetal bovine serum (FBS; ThermoFisher Scientific, Waltham, 
MA, USA), 100 U/mL penicillin, and 100 μg/mL streptomycin (GE 
Healthcare, Salt Lake City, UT, USA). Hep G2 (ATCC HB-8065) cells 
were maintained in modified Eagle’s medium (Hyclone, South Logan, 
UT, USA) supplemented with 10 % FBS and penicillin–streptomycin. All 
cells were maintained at 37 ◦C in an incubator in an atmosphere con-
taining 5% CO2. Cells were transfected with the same concentrations of 
scrambled or gene-targeted siRNAs for 24 h using Lipofectamine 
RNAiMAX (Invitrogen, Carlsbad, CA, USA). All siRNA duplexes were 
purchased from Integrated DNA Technologies. All plasmids were puri-
fied using an endotoxin-free purification system (Qiagen, Hilden, North 
Rhine-Westphalia, Germany) and transfected into cells using Lipofect-
amine 2000 (Invitrogen) for 24 h. Transfected cells were then cultured 
in fresh complete medium and analyzed as indicated in the figure 
legends. 
4.2. Immunofluorescence and EdU staining, and image analysis 
Cells were plated on LabTek chamber slides (Thermo Fisher Scien-
tific), cultured for 1 day, and then fixed with 100 % methanol at 20 ◦C 
for 30 min. For chromatin-bound proteins, cells were pretreated with 0.5 
% Triton X-100 for 2 min before fixation. For UV micro-irradiation, UVA 
laser (55 mW) irradiation was performed by means of a Palm Micro-
Beam laser microdissection workstation. The fixed cells were stained 
with the indicated primary antibodies overnight at 4 ◦C. After washes 
with 0.05 % Triton X-100, Alexa Fluor 488–, 568–, and 633–conjugated 
secondary antibodies (Invitrogen) were added and incubated for 1 h. 
The stained cells were mounted. EdU staining was performed by using 
Click-iT EdU assay kit (Invitrogen). Images were acquired on an 
Olympus FV1000 confocal fluorescence microscope and processed using 
the Olympus Fluoview or ImageJ software. 
4.3. Immunoprecipitation 
To prepare the total cell lysates, cells were washed three times with 
ice-cold PBS, and lysed and incubated with RIPA buffer on ice [37]. The 
lysates were incubated with the indicated antibody overnight at 4 ◦C 
under rotary agitation, followed by incubation with Protein A/G 
Sepharose beads (GE Healthcare Sciences) for 2 h. 
Bead–antibody–antigen complexes were pelleted by centrifugation at 4 
◦C for 1 min, and the supernatant was removed. The beads were washed 
three times for 10 min at 4 ◦C in RIPA buffer, resuspended in sample 
buffer, and boiled at 95 ◦C for 5 min. The complexes were analyzed by 
immunoblotting. 
4.4. Immunoblotting 
Cells were washed twice with cold PBS and lysed in RIPA buffer (0.01 
M Tris pH 7.4, 0.15 M NaCl, 0.001 M EDTA, 0.001 M EGTA, 1 % Triton X 
100; all from Sigma-Aldrich, Saint Louis, MO, USA) containing 2 μM 
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PMSF (Sigma-Aldrich) and protease inhibitors (Roche, Rotkreuz, 
Switzerland). After centrifugation of the lysate, the supernatant was 
used for immunoblot analysis. Protein concentration was measured 
using the BCA protein assay system (Pierce Biotechnology, Rockford, IL, 
USA). Proteins were denatured in Laemmli buffer. Equal amounts of 
protein from each sample were separated on SDS-PAGE gels and trans-
ferred to PVDF membranes. Blocking, incubation with primary anti-
body, and washing of the membrane were performed in PBS 
supplemented with 0.05 % Tween-20 (v/v) and 5 % (w/v) non-fat dry 
milk. The primary antibodies used for immunoblotting were anti- 
TonEBP (16; 1:3000), anti-Myc-tag (#2778), anti-PAR (#83732) (all 
from Cell Signaling Technology, Danvers, MA, USA), anti-FLAG tag 
(#F1804, Sigma-Aldrich), anti-S9.6 (#ENH001, Kerafast, Boston, MA, 
USA), and anti-PARP1 (#ab227244, Abcam, Cambridge, UK). All anti-
bodies were used at a 1:1000 dilution unless stated otherwise. Horse-
radish peroxidase-conjugated goat anti-mouse (62-6520; Thermo Fisher 
Scientific) or anti-rabbit (65-6120; Thermo Fisher Scientific) secondary 
antibodies were diluted 1:5000. Reactive bands were detected by 
chemiluminescence on an ImageQuant LAS 4000 imaging system (GE 
Healthcare). 
4.5. Proximity ligation assay 
For the PLA, cells were pre-extracted with cold 0.5 % NP-40 for 3 min 
on ice. The cells were then fixed with 4% PFA/PBS for 15 min, washed 
three times with PBS, and blocked for 1 h at RT with 2% BSA/PBS. The 
fixed and blocked cells were incubated with primary antibody overnight 
at 4 ◦C. The next day, the cells were washed three times in PBS and 
incubated in a pre-mixed solution of PLA probe anti-mouse minus and 
PLA probe anti-rabbit plus (Sigma-Aldrich) for 1 h at 37 ◦C. The Duolink 
In Situ Detection Reagents (Green) were used to perform the PLA reac-
tion. Slides were mounted in Duolink In Situ Mounting Medium with 
DAPI and imaged on a Zeiss Axioscope at 40 × . PLA foci were quantified 
using the ImageJ software. 
4.6. Cell survival analysis 
U2OS and HepG2 cells were plated in triplicate in 96-well plates and 
subjected to the MTT assay. Absorbance at 490 nm was measured using a 
multi-well plate reader. LDH release was calculated as a percentage 
using the following formula:  
percentage = (sample–spontaneous release/maximum release − spontaneous 
release) × 100.                                                                                       
4.7. S9.6 IP 
Cells were trypsinized, washed with PBS, and resuspended in 25 mL 
PBS. The cells were then crosslinked in 1 % formaldehyde (Pierce 
Biotechnology, Rockford, IL, USA), quenched with 0.125 M glycine, and 
washed twice in PBS containing protease inhibitor (PI; Roche). The fixed 
cells were lysed with lysis buffer (50 mM HEPES pH 7.9, 140 mM NaCl, 1 
mM EDTA, 10 % glycerol, 0.5 % NP-40, 0.25 % Triton X-100) with 
proteinase inhibitor cocktail, and chromatin was sonicated in shearing 
buffer (0.1 %SDS, 1 mM EDTA, 10 mM Tris pH 8.1) on a ultrasonicator 
(Covaris, Woburn, MA, USA) to an average size of 1 kb. Washed Protein 
A/G Sepharose beads (Pierce Biotechnology) were used to pre-clear 
chromatin for 2 h. Ten micrograms of the chromatin fraction was 
mixed with either 20 μg S9.6 antibody or 20 μg mouse IgG, and incu-
bated overnight at 4 ◦C. Pre-washed Protein A/G Sepharose beads were 
then added to the chromatin/antibody mixture for 2 h. After washing 
three times with binding buffer (10 mM NaPO4 pH 7, 140 mM NaCl, 0.05 
% Triton X-100), bound beads were boiled in 30 μL 5X sample buffer (10 
% SDS, 500 mM DTT, 50 % glycerol, 250 mM Tris-HCL and 0.5 % 
bromophenol blue dye, pH 6.8) and loaded on a 4–20 % gradient gel 
(Bio-Rad, Hercules, CA, USA). 
4.8. Statistical analysis 
Data are expressed as the mean ± standard deviation or standard 
error of the mean. The statistical significance of differences between two 
conditions was estimated using the unpaired t-test. Comparisons be-
tween more than two conditions were evaluated by one-way ANOVA 
with Tukey’s post-hoc test. A p-value < 0.05 was deemed significant. All 
statistical analyses were performed using the GraphPad Prism 8.2 soft-
ware (GraphPad, San Jose, CA, USA). 
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